Helaina

Market position

Helaina describes effera as the first human lactoferrin to reach the market, differentiated from bovine lactoferrin, which is expensive to purify from cow's milk and in short supply. Other companies produce bovine lactoferrin via precision fermentation for adult nutrition; Helaina positions the human version as a premium option. In infant nutrition it has been compared with Bobbie, ByHeart and Biomilq, the latter producing cell-cultured human milk.

The company positions its protein as bio-identical/human-equivalent rather than an animal-derived substitute, citing clinical data that the body does not produce antibodies against it (unlike bovine lactoferrin), up to 4x better absorption than the bovine version, and a 63% reduction in inflammation in ex vivo human immune cell studies. Management also argues the unit economics of precision fermentation work because effera replaces a high-value, supply-constrained ingredient rather than a commoditized one.

Technology

A yeast-based precision fermentation platform, powered by an in-house machine learning model, that reprograms microbial cells to express human bioactive proteins. Helaina has stated its proteins are 99% identical to those in breastmilk. Production has been scaled through contract manufacturers to metric-ton scale, with the company citing runs supporting 10 million servings. Supporting evidence includes ex vivo human immune cell studies and clinical studies of adult safety and immunogenicity.

Go-to-market

Ingredient supply agreements with consumer brands and specialty distributors, supported by clinical and pre-clinical evidence that enables customer claims around immunity, iron status, bone health around menopause, prebiotic effects and inflammation. Named brand partners include Kroma Wellness, The Feed, Levelle Nutrition, Healthgevity, Desert Harvest, Amulet and Mitsubishi International Food Ingredients, plus a partnership with Nestlé in early-life nutrition.

Consumer brands and ingredient distributors formulating functional foods, beverages and dietary supplements; end-user categories include women's health, active nutrition and athletes, healthy aging/longevity, gut health, hair and skin, and prospectively infant formula for parents.

Geography

Headquartered in New York; the company operated a laboratory in New York City for microbe production, fermentation and immunity testing, and scales manufacturing via contract manufacturers. Distribution partners include Mitsubishi International Food Ingredients.

History

Founded in 2019 in New York City by food scientist Laura Katz, Helaina raised a combined $4.6 million in pre-seed and seed rounds across 2019 and 2020, followed by a $20 million Series A in November 2021 that brought total funding to $24.6 million and funded build-out of its proprietary technology stack and proof that it could produce human proteins outside the body. In 2022 the company established commercial-scale manufacturing, and in 2023 ran its first clinical study to verify the adult safety of effera. A $45 million Series B, announced in 2024 and led by Avidity Partners, brought equity funding to $83 million and supported the shift from an R&D organization to a commercial enterprise. In 2025 the company reported metric-ton scale manufacturing of effera and launches in multiple consumer products, and in June 2026 announced a partnership with Nestlé on bioactive proteins for early-life nutrition.

Risks & controversies

Helaina's CEO declined to comment publicly on effera's GRAS regulatory status as of 2024, and the company earlier stated it was seeking FDA approval for its infant product. Management has characterized the funding environment as difficult and noted precision fermentation is costly, limiting its use to high-value ingredients. A key clinical study cited by the company was still undergoing peer review at the time of reporting. Efficacy figures such as the 63% inflammation reduction and 4x absorption are company-reported.